{"atc_code":"C10B","metadata":{"last_updated":"2020-09-06T07:03:53.893738Z","applied_components":{"decision_date_extraction":{"output_fields":["attachment.decision_date"],"input_checksum":"5190403d8ca808fc00954ea99be63bcbe228d58f9b00dc20f3d823c2a3479b8e","last_success":"2021-01-21T17:04:19.954974Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"decision_date_extraction","input_fields":["attachment.type","attachment.content"],"version":1,"finish_time":"2021-01-21T17:04:19.954974Z","status":"NOT_APPLICABLE"},"study-ids-enricher":{"output_fields":["attachment.studies","attachment.max_study_phase"],"input_checksum":"14d9cbc4c5a3598e98ce35beaefc3fe741ef666d9915d371e93f6372b706f94c","last_success":"2021-01-21T17:01:52.993009Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"study-ids-enricher","input_fields":["attachment.type","active_substance","attachment.content"],"version":27,"finish_time":"2021-01-21T17:01:52.993009Z","status":"NOT_APPLICABLE"},"EmaDataAccessor":{"output_fields":[],"input_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","last_success":"2020-09-06T07:03:53.893724Z","output_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","success":true,"name":"EmaDataAccessor","input_fields":[],"version":3,"finish_time":"2020-09-06T07:03:53.893724Z","status":"UP_TO_DATE"},"historic_pivotal_studies":{"output_fields":["attachment.studies.known_pivotal"],"input_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","last_success":"2020-09-10T12:24:15.095668Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"historic_pivotal_studies","input_fields":["attachment.studies.study_ids"],"version":2,"finish_time":"2020-09-10T12:24:15.095668Z","status":"UP_TO_DATE"},"section_ranges_extraction":{"output_fields":["attachment.labelSections"],"input_checksum":"5190403d8ca808fc00954ea99be63bcbe228d58f9b00dc20f3d823c2a3479b8e","last_success":"2020-11-19T18:42:17.093009Z","output_checksum":"6f55c8ef4d5762d42c5a0996a3602ce93c03d6b6006e3d3a0648bfdb3d1643ab","success":true,"name":"section_ranges_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2020-11-19T18:42:17.093009Z","status":"UP_TO_DATE"},"AttachmentDownloader":{"output_fields":["attachment.content","attachment.first_published","attachment.last_updated"],"input_checksum":"e5bc12498b92321c06d9a7626819ff2adc77853a396095de8f99235956aed1d0","last_success":"2020-09-06T10:43:33.440488Z","output_checksum":"f3ef83f81a1d39c07c0ff2ba187005cd5fd8a670171ba5453c6096564a0699df","success":true,"name":"AttachmentDownloader","input_fields":["attachment.link"],"version":2,"finish_time":"2020-09-06T10:43:33.440488Z","status":"UP_TO_DATE"},"prime_designation_enricher":{"output_fields":["prime_designation"],"input_checksum":"5190403d8ca808fc00954ea99be63bcbe228d58f9b00dc20f3d823c2a3479b8e","last_success":"2020-11-18T17:33:17.265397Z","output_checksum":"dcf4d2ed94fa29974e643bd4a70cd26ec785f1130958f3e23e8022193699a97a","success":true,"name":"prime_designation_enricher","input_fields":["attachment.type","attachment.content"],"version":3,"finish_time":"2020-11-18T17:33:17.265397Z","status":"UP_TO_DATE"},"rapporteur_extraction":{"output_fields":["attachment.co_rapporteur","attachment.main_rapporteur"],"input_checksum":"5190403d8ca808fc00954ea99be63bcbe228d58f9b00dc20f3d823c2a3479b8e","last_success":"2021-01-21T17:12:24.604286Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"rapporteur_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2021-01-21T17:12:24.604286Z","status":"NOT_APPLICABLE"}},"agency":"EMA","product_id":"5D12E189A7678E35C23B07BC2F212DFB","direct_link":"https://www.ema.europa.eu/en/medicines/human/EPAR/nustendi","first_created":"2020-09-06T07:03:53.891625Z","component_failures":{"section_ranges_extraction":"com.bayer.rapid.rest.RestEnricherException: Enricher returned error code 500, message: Internal Server Error","prime_designation_enricher":"com.bayer.rapid.rest.RestEnricherException: Enricher returned error code 500, message: Internal Server Error"}},"revision_number":2,"approval_status":"authorised","active_substance":["Bempedoic acid","Ezetimibe"],"additional_monitoring":true,"inn":["bempedoic acid","ezetimibe"],"prime_designation":false,"accelerated_assessment":false,"orphan":false,"product_name":"Nustendi","authorization_holder":"Daiichi Sankyo Europe GmbH","generic":false,"product_number":"EMEA/H/C/004959","initial_approval_date":"2020-03-27","attachment":[{"last_updated":"2020-08-31","labelSections":{"name":"HEADER","start":0,"end":318},"oldtype":"product-information","link":"https://www.ema.europa.eu/documents/product-information/nustendi-epar-product-information_en.pdf","id":"6766CEDEE834A41AFDE6BFF65C4A70A5","type":"productinformation","title":"Nustendi : EPAR - Product information","first_published":"2020-04-24","content":"30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom \n\nAn agency of the European Union  \n\nTelephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 \nSend a question via our website www.ema.europa.eu/contact \n \n\n© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. \n\n16 December 2015 \nEMA/749945/2015 \nProcedure Management and Committees Support Division \n\nChecklist for the submission of Type IA and Type IB \n(without linguistic review) product information annexes \nand Annex A (if applicable) \n\nFor the submission of the full set of annexes, [i.e. Annex I (SmPC), Annex II, \nAnnex IIIA (labelling), Annex IIIB (package leaflet) and Annex A (if applicable)] \nin all EEA languages, the applicant/MAH confirms that they have prepared the files \nin accordance with the following checklist: \n\nTick to \nconfirm \ncheck \n\nThe QRD Convention published on the Agency’s website was followed for the preparation of \nthe Word source files \n\nThe User guide on how to generate PDF versions of the product information and other \nannexes published on the Agency’s website was followed for the preparation of the PDF files \n\nThe PDF versions in all EEA languages are identical to the Word source files \n\nTrack changes and comments have been ‘accepted’ (not simply switched off) and coloured \nor highlighted text does not appear in the PDF versions (except for sections referring to \nAppendix V) \n\nThe marketing authorisation dates of first authorisation (dates for different presentations to \nreflect the date of the first authorisation) and latest renewal, if any, are correct and \nindicated in section 9 of the SmPC, as appropriate \n\nRevision dates do not appear in section 10 (‘Date of revision of the text’) of the SmPC \n\nRevision dates do not appear in section “This leaflet was last approved on” of the package \nleaflet \n\nPictures in the SmPC and package leaflet display correctly and do not overlap with the text. \nThey appear in the correct order and references made to picture numbers in the text are \ncorrect. The entire text in pictures was translated into the respective EEA language \n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\n\n\nChecklist for the submission of Type IA and Type IB (without linguistic review) product information \nannexes and Annex A (if applicable) \nEMA/749945/2015 Page 2/2 \n\nFor the submission of the full set of annexes, [i.e. Annex I (SmPC), Annex II, \nAnnex IIIA (labelling), Annex IIIB (package leaflet) and Annex A (if applicable)] \nin all EEA languages, the applicant/MAH confirms that they have prepared the files \nin accordance with the following checklist: \n\nTick to \nconfirm \ncheck \n\nThere are no blank pages or unexpected blank spaces (note: half empty pages are \nacceptable if they occur in connection with tables or pictures) \n\nThere is no text in the header of the pages \n\nOnly page numbers appear in the footer of the pages, starting with ‘1’ (bottom, centre) on \nthe title page of Annex I. The font used is Arial, size 8 \n\nFull set of annexes is provided as an integrated document in Word (with tracked changes) \nin each EEA language in the 'Working document' folder, outside the eCTD structure.  \n\nThe font used for the text is Times New Roman, size 11, and Arial, size 8, for the page \nnumber \n\nFull set of annexes is provided in clean PDF format in each EEA language under Mod.1.3.1 \n\nThe PDF files follow the naming convention ema-combined-hxxx<language code>; \nbookmarks and document properties are added as per guideline \n\nAnnex A (if applicable) is provided as a separate document in clean PDF format in each EEA \nlanguage (one document per language) under Mod.1.2.  \n\nThe cover page ‘Annex A’ is removed, the font used is Verdana, size 9, for the text and \nArial, size 8, for the page number \n\nThe PDF files follow the naming convention ema-other-hxxx-aa<language \ncode>; document properties are added as per guideline \n\nAnnex A is provided in Word (with tracked changes) in EN only in the 'Working documents' \nfolder, outside the eCTD structure \n\nAnnex A table headings are in accordance with the latest QRD template \n\nConfirmed by: \n\nName: Dr. Alexandra Mees Signature: ______________________     Date: June 15, 2020\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\n\n\tEMA - Checklist for the submission of product information annexes","content_length":4307,"file_size":153207}],"conditional_approval":false,"exceptional_circumstances":false,"indication":"<div> \n <div class=\"ecl-field__body\"> \n  <div class=\"ecl-editor first last\">\n   <p>Nustendi is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:</p> \n   <ul>\n    <li>in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe</li> \n    <li>alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,</li> \n    <li>in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin</li> \n   </ul>\n  </div> \n </div> \n</div>","therapeutic_area":["Hypercholesterolemia","Dyslipidemias"],"contact_address":"Zielstattstrasse 48\n81379 Munich\nGermany","biosimilar":false}